Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects

Aims The safety and pharmacokinetics of single and multiple doses of a novel mGlu2/3 receptor agonist prodrug, MGS0274 besylate (TS‐134), were investigated in healthy subjects. Methods Phase 1 single‐ascending dose (5–20 mg) and multiple‐ascending dose titration (5–80 mg) studies were conducted in h...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2020-11, Vol.86 (11), p.2286-2301
Hauptverfasser:	Watanabe, Mai, Marcy, Brian, Kinoshita, Kohnosuke, Fukasawa, Misako, Hikichi, Hirohiko, Chaki, Shigeyuki, Okuyama, Shigeru, Gevorkyan, Hakop, Yoshida, Shigeru
Format:	Artikel
Sprache:	eng
Schlagworte:	cerebrospinal fluid mGlu2/3 agonist MGS0008 MGS0274 Original schizophrenia TS‐134
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!